Analytical Data
-
Gene name
NYREN18
- Application
-
Alternative Names
BS4; NEDD8 ultimate buster 1; Negative regulator of ubiquitin like proteins 1; Negative regulator of ubiquitin-like proteins 1; NUB1; NUB1_HUMAN; NUB1L; NY REN 18; NYREN18; Renal carcinoma antigen NY-REN-18
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y5A7
-
Expression Region
1-615 aa
-
AA Sequence
MAQKKYLQAK LTQFLREDRI QLWKPPYTDE NKKVGLALKD LAKQYSDRLE CCENEVEKVI EEIRCKAIER GTGNDNYRTT GIATIEVFLP PRLKKDRKNL LETRLHITGR ELRSKIAETF GLQENYIKIV INKKQLQLGK TLEEQGVAHN VKAMVLELKQ SEEDARKNFQ LEEEEQNEAK LKEKQIQRTK RGLEILAKRA AETVVDPEMT PYLDIANQTG RSIRIPPSER KALMLAMGYH EKGRAFLKRK EYGIALPCLL DADKYFCECC RELLDTVDNY AVLQLDIVWC YFRLEQLECL DDAEKKLNLA QKCFKNCYGE NHQRLVHIKG NCGKEKVLFL RLYLLQGIRN YHSGNDVEAY EYLNKARQLF KELYIDPSKV DNLLQLGFTA QEARLGLRAC DGNVDHAATH ITNRREELAQ IRKEEKEKKR RRLENIRFLK GMGYSTHAAQ QVLHAASGNL DEALKILLSN PQMWWLNDSN PETDNRQESP SQENIDRLVY MGFDALVAEA ALRVFRGNVQ LAAQTLAHNG GSLPPELPLS PEDSLSPPAT SPSDSAGTSS ASTDEDMETE AVNEILEDIP EHEEDYLDST LEDEEIIIAE YLSYVENRKS ATKKN
-
Molecular Weight
70.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NYREN18 is a novel recombinant protein derived from a specific antigen that has been identified as a promising target in cancer immunotherapy. Developed through advanced recombinant DNA technology, NYREN18 is primarily recognized for its ability to elicit a strong immune response against certain types of tumors, particularly renal cell carcinoma. The research into NYREN18 is driven by the increasing need for effective cancer treatments that harness the body’s immune system. Previous studies have highlighted the potential of NYREN18 to activate T cells, thus enhancing their ability to recognize and destroy cancer cells. This protein operates by presenting tumor-associated antigens to the immune system, facilitating a targeted attack on malignant cells while sparing healthy tissue. Ongoing investigations aim to elucidate the precise mechanisms of NYREN18-induced immune activation and to evaluate its efficacy in various preclinical and clinical settings. Ultimately, the development of NYREN18 holds promise for improving cancer therapy outcomes and represents a step forward in the field of personalized medicine. As researchers continue to explore the intricacies of NYREN18 and similar recombinant proteins, the goal is to pave the way for innovative immunotherapeutic strategies that may offer hope to patients battling cancer.
